Evidence map›Paper›PMID 38814917›Full record

ArticlePloS one2024

Knowledge and practices regarding prostate cancer screening in Spanish men: The importance of personal and clinical characteristics (PROSHADE study).

Lucy A Parker, Juan-Pablo Caballero-Romeu, Elisa Chilet-Rosell, Ildefonso Hernandez-Aguado, Luis Gómez-Pérez, Pablo Alonso-Coello, Ana Cebrián, Maite López-Garrigós, Irene Moral-Pélaez, Elena Ronda and 5 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lucy A ParkerDepartment of Public Health, History of Science and Gynecology, Miguel Hernandez University, San Juan de Alicante, Spain.
Juan-Pablo Caballero-RomeuDepartment of Urology, Dr. Balmis General University Hospital; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Elisa Chilet-RosellDepartment of Public Health, History of Science and Gynecology, Miguel Hernandez University, San Juan de Alicante, Spain.
Ildefonso Hernandez-AguadoDepartment of Public Health, History of Science and Gynecology, Miguel Hernandez University, San Juan de Alicante, Spain.
Luis Gómez-PérezDepartment of Urology, University General Hospital of Elche, Elche, Spain.
Pablo Alonso-CoelloIberoamerican Cochrane Centre - Department of Clinical Epidemiology and Public Health, Biomedical Re-search Institute Sant Pau, Barcelona, Spain.
Ana CebriánCartagena Casco Healthcare Centre, Cartagena, Spain.ORCID 0000-0003-3710-6370
Maite López-GarrigósCIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Irene Moral-PélaezEAP Sardenya, Barcelona. Institut de Recerca Sant Pau, Barcelona, Spain.
Elena RondaCIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Mercedes GilabertDepartment of Health Psychology, Miguel Hernandez University, Elche, Spain.
Carlos Canelo-AybarCIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Ignacio Párraga-MartínezHealth Care Center Zone VIII, Servicio de Salud Castilla-La Mancha, Albacete, Spain.
Ma Del Campo-GiménezIntegrated Care Management of Albacete. Health Service of Castilla-La Mancha, Spain.ORCID 0000-0002-9565-4351
Blanca LumbrerasDepartment of Public Health, History of Science and Gynecology, Miguel Hernandez University, San Juan de Alicante, Spain.ORCID 0000-0003-1665-0860

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients' decisions on prostate cancer (PCa) opportunistic screening may vary. This study aimed to assess how demographic and health-related characteristics may influence knowledge and decisions regarding PCa screening.

methodsA cross-sectional survey was conducted among men aged over 40, randomly sampled from the Spanish population, 2022. The survey underwent development and content validation using a modified Delphi method and was administered via telephone. Binomial logistic regression was used to explore the relationship between respondents' characteristics and participants' knowledge and practices concerning PCa and the PSA test.

resultsOut of 1,334 men, 1,067 (80%) respondents were interviewed with a mean age of 58.6 years (sd 11.9). Most had secondary or university studies (787, 73.8%) and 61 (5.7%) self-reported their health status as bad or very bad. Most of the respondents (1,018, 95.4%) had knowledge regarding PCa with nearly 70% expressed significant concern about its potential development (720, 70.8%), particularly among those under 64 years (p = 0.001). Out of 847 respondents, 573 (67.7%) reported that they have knowledge regarding the PSA test: 374 (65.4%) reported receiving information from a clinicians, 324 (86.6%) information about the benefits of the test and 189 (49,5%) about its risks, with differences based on educational background. In a multivariable analysis (adjusted for age, educational level and previous prostate problems), respondents with higher levels of education were more likely to have higher knowledge regarding the PSA test (OR 1.75, 95%CI 1.24-2.50, p<0.001).

conclusionsAlthough most of the patients reported to have knowledge regarding PCa, half of the interviewed men reported knowledge about PSA test. Differences in knowledge prostate cancer screening and undesirable consequences highlight the need to develop and provide tailored information for patients.

Indexed as

Early Detection of CancerHealth Knowledge, Attitudes, PracticeProstatic NeoplasmsAdultAgedCross-Sectional StudiesHumansMaleMiddle AgedProstate-Specific AntigenSpainSurveys and QuestionnairesProstate-Specific Antigen

Identifiers

PMID38814917
PMCPMC11139292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.